 | |
| Clinical data | |
|---|---|
| Other names | KDS-2010; KDS2010; SeReMABI |
| Drug class | Reversiblemonoamine oxidase B (MAO-B)inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H17F3N2O |
| Molar mass | 322.331 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tisolagiline (INNTooltip International Nonproprietary Name; developmental code namesKDS-2010,SeReMABI) is apotent, highlyselective, andreversiblemonoamine oxidase B (MAO-B)inhibitor which is under development for the treatment ofAlzheimer's disease andobesity.[1][2][3][4] It is takenby mouth.[1] Tisolagiline is being developed by NEUROBiOGEN and Scilex Bio.[1][2] As of December 2024, it is inphase 2clinical trials for Alzheimer's disease and obesity.[1][2]
In 2025, research suggested that KDS-2010 could also be used in recovery ofspinal cord injuries. In these injuries, there is an excess ofglia cells which protect the site but inhibit neural repair. Use of the MAO-B inhibitor in animal models resulted in improved neurological and locomotor abilities.[5][6]
4.4. KDS2010 A recently developed KDS2010, which is ~12,500-fold more selective to MAOB than MAOA, differentiates the role of MAOB from MAOA and reports that MAOB does not contribute to DA degradation [39]. KDS2010 is a potent (IC50 = 7.6 nM), and selective MAOB inhibitor named shows no known off-target effect (no other enzymes or channels causing >40% inhibition) or toxicity for 4 weeks of repeated dosing in non-human primates [16,41]. KDS2010 was turned out to be highly effective for alleviating the PD-related motor symptoms and PD-like pathology, including reactive astrogliosis, excessive astrocytic GABA, and nigrostriatal DAergic neuronal loss in multiple rodent models of PD [41]. Its clinical efficacy is still waiting to be tested in future studies.
KDS2010 is a novel compound highly potent and selective reversible MAO-B inhibitor (Fig. 2). It has demonstrated learning and memory improvements, promotion of synaptic transmission, and reduction of astrogliosis and astrocytic GABA levels in APP/presenilin 1 mice (Park et al. 2019).
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |